---
title: "603566.SH (603566.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/603566.SH/news.md"
symbol: "603566.SH"
name: "603566.SH"
parent: "https://longbridge.com/en/quote/603566.SH.md"
datetime: "2026-05-21T06:19:52.259Z"
locales:
  - [en](https://longbridge.com/en/quote/603566.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/603566.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/603566.SH/news.md)
---

# 603566.SH (603566.SH) — Related News

### [PULIKE: "Pregabalin Oral Solution" has obtained a new veterinary drug registration certificate](https://longbridge.com/en/news/286732439.md)
*2026-05-18T07:42:04.000Z*
> PULIKE announced that its new veterinary drug "Pregabalin Oral Solution" has been approved for registration by the Minis

### [PULIKE: Obtained the new veterinary drug registration certificate for the canine distemper and parvovirus bivalent live vaccine](https://longbridge.com/en/news/282961036.md)
*2026-04-16T08:07:22.000Z*
> PULIKE announced that the "Canine Distemper and Parvovirus Combined Live Vaccine" jointly declared by the company and it

### [Galaxy Securities: Focus on the balanced layout opportunities in the pig farming industry](https://longbridge.com/en/news/273762286.md)
*2026-01-27T00:12:17.000Z*
> Galaxy Securities focuses on the layout opportunities in the pig farming industry, pointing out that this year's pig pri

### [PULIKE issued a profit forecast, expecting a net profit attributable to the parent company of 176 million to 195 million yuan in 2025, an increase of 89.64% to 110.11%](https://longbridge.com/en/news/273046901.md)
*2026-01-20T07:48:04.000Z*
> PULIKE expects the net profit attributable to the parent company in 2025 to be between 176 million yuan and 195 million 

### [PULIKE: Subsidiary obtains new veterinary drug registration certificate for the three-inactivated vaccine against Newcastle disease and others](https://longbridge.com/en/news/272383047.md)
*2026-01-13T08:46:23.000Z*
> PULIKE announced that its wholly-owned subsidiary Luoyang Huizhong Biotechnology Co., Ltd. and other units jointly appli

### [PULIKE has obtained a new veterinary drug registration certificate](https://longbridge.com/en/news/271898684.md)
*2026-01-08T08:18:04.000Z*
> PULIKE has obtained a new veterinary drug registration certificate, approving the joint application of "Fluralaner Chewa

### [PULIKE: Subscription for equity in Zhongpu Biotech](https://longbridge.com/en/news/269825861.md)
*2025-12-16T07:38:30.000Z*
> PULIKE announced that the company acquired 4.04% equity in Zhongpu Biopharmaceutical Co., Ltd. for 17.5143 million yuan.

### [PULIKE strategically invests in Zhongpu Biopharmaceutical](https://longbridge.com/en/news/268247162.md)
*2025-12-02T12:07:18.000Z*
> PULIKE announced the completion of a strategic investment in Zhongpu Biopharmaceuticals, aiming to strengthen cooperatio